accretive health

Sterne Agee Drops Coverage of Accretive Health (AH) Sterne Agee is dropping coverage of Accretive Health (NYSE: AH). Shares of AH closed Monday at $24.90, down 1.97% from Friday's close.

Goldman Sachs is out with its report today on Accretive Health (NYSE: AH), raising its PT from $14 to $21. In a note to clients, Goldman Sachs states, "We increase our 12 month price target to $21 from $14, which is based on a blend of our EV/EBITDA (50%), PEG (30%), and DCF (20%) valuation...

J.P. Morgan reports that in the area of health care IT, its two top picks for 2011 are Accretive Health, Inc. (NYSE: AH) and Allscripts Healthcare Solutions (NASDAQ: MDRX). “We view AH as an underappreciated story with the best growth prospects in our coverage universe, and multiple expansion from...

Goldman Sachs has published a research report on Accretive Health, Inc. (NYSE: AH) after meeting with company management. In the report, Goldman Sachs writes "We provide key points from meetings with Accretive Health (AH, Neutral) management and investors: (1) AH emphasized its confidence in the $...

JP Morgan has published a research report on Accretive Health (NYSE: AH) after the company reported revenue shortfalls in its 3Q. In the report, JP Morgan writes "AH shares traded down 7.7% yesterday (vs. -0.4% for the S&P 500) after reporting 3Q EPS that was in line with consensus of $0.06,...

Accretive Health, Inc. (NYSE: AH) reported 3Q 2010 results, Goldman Sachs reports, noting that the EPS of $0.06 and adjusted EBITDA of $32.2 were both in-line with GS/Street estimates. “However, revenues of $158.4 were significantly below our estimate of $174.6mn and Street consensus of $172.4mn,”...

Brean Murray Carret & Co. has initiated coverage for the following companies: Accretive Health Inc. (NYSE: AH) Hold, N/A price target, $10.81 MedAssets, Inc. (NASDAQ: MDAS) Buy, $25 price target, $20.37 Is AAPL a Buy, Sell or Hold? Click Here.